Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds expression product or fragment thereof of...
Reexamination Certificate
2008-05-13
2008-05-13
Harris, Alana M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds expression product or fragment thereof of...
C424S130100, C424S133100, C424S141100, C424S142100, C424S143100, C424S155100, C424S156100, C424S174100
Reexamination Certificate
active
10600152
ABSTRACT:
The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.
REFERENCES:
patent: 4676980 (1987-06-01), Segal et al.
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4935341 (1990-06-01), Bargmann et al.
patent: 4943533 (1990-07-01), Mendelsohn et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5169774 (1992-12-01), Frankel et al.
patent: 5183884 (1993-02-01), Kraus et al.
patent: 5288477 (1994-02-01), Bacus
patent: 5359046 (1994-10-01), Capon et al.
patent: 5367060 (1994-11-01), Vandlen et al.
patent: 5401638 (1995-03-01), Carney et al.
patent: 5464751 (1995-11-01), Greene et al.
patent: 5480968 (1996-01-01), Kraus et al.
patent: 5578482 (1996-11-01), Lippman et al.
patent: 5604107 (1997-02-01), Carney et al.
patent: 5641869 (1997-06-01), Vandlen et al.
patent: 5663144 (1997-09-01), Greene et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5705157 (1998-01-01), Greene
patent: 5720937 (1998-02-01), Hudziak et al.
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5726023 (1998-03-01), Cheever et al.
patent: 5728687 (1998-03-01), Bissery
patent: 5747261 (1998-05-01), King et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5801005 (1998-09-01), Cheever et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5824311 (1998-10-01), Greene et al.
patent: 5834229 (1998-11-01), Vandlen et al.
patent: 5837243 (1998-11-01), Deo et al.
patent: 5837523 (1998-11-01), Greene et al.
patent: 5840525 (1998-11-01), Vandlen et al.
patent: 5846538 (1998-12-01), Cheever et al.
patent: 5856110 (1999-01-01), Vandlen et al.
patent: 5859206 (1999-01-01), Vandlen et al.
patent: 5869445 (1999-02-01), Cheever et al.
patent: 5876712 (1999-03-01), Cheever et al.
patent: 5877305 (1999-03-01), Huston et al.
patent: 5908835 (1999-06-01), Bissery
patent: 5910486 (1999-06-01), Curiel et al.
patent: 5922845 (1999-07-01), Deo et al.
patent: 5939531 (1999-08-01), Wels et al.
patent: 5968511 (1999-10-01), Akita et al.
patent: 5977322 (1999-11-01), Marks et al.
patent: 5985553 (1999-11-01), King et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6028059 (2000-02-01), Curiel et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6054561 (2000-04-01), Ring
patent: 6096873 (2000-08-01), Schaefer et al.
patent: 6123939 (2000-09-01), Shawver et al.
patent: 6165464 (2000-12-01), Hudziak et al.
patent: 6333348 (2001-12-01), Vogel et al.
patent: 6627196 (2003-09-01), Baughman et al.
patent: 6949245 (2005-09-01), Sliwkowski
patent: 2003/0086924 (2003-05-01), Sliwkowski
patent: 2004/0013667 (2004-01-01), Kelsey et al.
patent: 2004/0037824 (2004-02-01), Baughman et al.
patent: 2005/0208043 (2005-09-01), Adams et al.
patent: 2005/0238640 (2005-10-01), Sliwkowski
patent: 2006/0034842 (2006-02-01), Adams et al.
patent: 2006/0073143 (2006-04-01), Adams et al.
patent: 2006/0193854 (2006-08-01), Adams et al.
patent: 2006/0198843 (2006-09-01), Adams et al.
patent: 2006/0210561 (2006-09-01), Baughman et al.
patent: 2006/0216285 (2006-09-01), Adams et al.
patent: 0003089 (1979-07-01), None
patent: 0599274 (1994-06-01), None
patent: 616812 (1994-09-01), None
patent: 711565 (1998-08-01), None
patent: 3-240498 (1991-10-01), None
patent: 5-117165 (1993-05-01), None
patent: 5-170667 (1993-07-01), None
patent: 5-213775 (1993-08-01), None
patent: 5-317084 (1993-12-01), None
patent: 95006982 (1995-01-01), None
patent: 7-59588 (1995-03-01), None
patent: 2761543 (1998-06-01), None
patent: 2895105 (1999-05-01), None
patent: WO 89/06692 (1989-07-01), None
patent: WO 90/14357 (1990-11-01), None
patent: WO 91/00360 (1991-01-01), None
patent: WO 92/10573 (1992-06-01), None
patent: WO 92/20373 (1992-11-01), None
patent: WO 92/20798 (1992-11-01), None
patent: WO 93/12220 (1993-06-01), None
patent: WO 93/21232 (1993-10-01), None
patent: WO 93/21319 (1993-10-01), None
patent: WO 94/00136 (1994-01-01), None
patent: WO 94/04690 (1994-03-01), None
patent: WO 94/22478 (1994-10-01), None
patent: WO 94/28127 (1994-12-01), None
patent: WO 95/16051 (1995-06-01), None
patent: WO 95/17507 (1995-06-01), None
patent: WO 95/28485 (1995-10-01), None
patent: WO 96/18409 (1996-06-01), None
patent: WO 96/27011 (1996-09-01), None
patent: WO 97/04801 (1997-02-01), None
patent: WO 97/20858 (1997-06-01), None
patent: WO 97/27848 (1997-08-01), None
patent: WO 97/35885 (1997-10-01), None
patent: WO 97/38731 (1997-10-01), None
patent: WO 98/02541 (1998-01-01), None
patent: WO 98/17797 (1998-04-01), None
patent: WO 98/45479 (1998-10-01), None
patent: WO 99/31140 (1999-06-01), None
patent: WO 99/48527 (1999-09-01), None
patent: WO 00/61185 (2000-10-01), None
patent: WO 01/00245 (2001-01-01), None
Seidman, A.D. et al., Seminars in Oncology, 22(5): 108-116, 1995.
Baselga, J. et al., Proceedings of the American Association for Cancer Research, 35: 380, Abstract #2262, 1994.
Baselga, J. et al, Breast Cancer Research and Treatment, 32(suppl): p. 30, Abstract #5, 1994.
Rohan, T.E., et al., Journal of the National Cancer Institute, 90(17): 1262-1269, 1998.
Arteaga et al., “pl85c-erb8-2Signaling Enhances Cisplatin-induced Cytotoxicity iin Human Breast Carcinoma Cells: Association Between an Ocogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair” Cancer Research 54 (14):3758-3765 (Jul. 15, 1994).
Bacus et al., “Differentiation of Cultured Human Breast Cancer Cells (AU-565 and MCF-7) Associated With Loss of Cell Surface HER-2
eu Antigen”Molecular Carcinogenesis3 (6):350-362 (1990).
Bacus et al., “tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of HUman Breast Cancer Cells”Cancer Research52(9) :2580-2589 (May 1, 1991).
Baselga and Mendelsohn, “Receptor Blockade With Monoclonal Antibodies As Anti-Cancer Therapy”Pharmac. Ther.64:127-154 (1994).
Baselga et a., “Anti HER2 Humanized Monoclonal Antibody (MAb) Alone and in Combination with Chemotherapy Against Human Breast Carcinoma Xenografts”Proceedings of ASCO-13th Annual Meeting(Abstract #), Dalllas, TX 13:63 (Mar 1994).
Baselga et al., “HER2 Overexpression and Paclitaxel Sensitivity in Breast Cancer: Therapeutic Implication”Onoclogy(Supplement No. 2) 11(3):43-48 (Mar. 1997).
Baselga et al., “Monoclonal Antibodies Directed Against Growth Factor Receptors Enhance the Efficacy of Chemotherapeutic Agents.”Annals of Oncology(abstract #010) 5(Suppl. 5) (1994).
Baselga et al., “Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2Monoclonal Antibody in Patients With HER2
eu-Overexpressing Metastatic Breast Cancer”J. Clin. Oncol.14(3):737-744 (Mar. 1996).
Baselga et al., “Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enchances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2
eu Overexpressing Human Breast Cancer Xenografts”CancerResearch 58:2825-2831 (Jul. 1998).
Carbonell Castellon et al., “Efficacy and safety of 3-weekly Herceptin (H) monotherapy in women with HER2-positive metastatic breast cancer (MBC): preliminary data from a phase II study”Proc Am Soc Clin Oncol(Abstract #73 from the 2002 ASCO Meeting) 21:19a (2002).
Carbonell et al., “Efficacy and safety of 3-weekly Herceptin monotherapy in women with HER2-positive metastatic breast cancer: preliminary data from a phase II study” (Oral presentation at the 38th Annual Meeting of the American Society of Clinical Oncology, May 18-21, 2002 in Orlando, Florida).
Carter et al., “Humanization of an Anti-p185HER2Anitbody For Human Cancer Therapy”Proc. Natl. Acad. Sci. USA89:4285-4289 (May 1992).
Chothia and Lesk, “Canonical Stru
Baughman Sharon A.
Shak Steven
Genentech Inc.
Harris Alana M.
Holleran Anne L.
Lee Wendy M.
LandOfFree
Dosages for treatment with anti-ErbB2 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dosages for treatment with anti-ErbB2 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dosages for treatment with anti-ErbB2 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3935742